Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,877
  • Shares Outstanding, K 13,550
  • Annual Sales, $ 10 K
  • Annual Income, $ -23,390 K
  • 36-Month Beta 5.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.34

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.05 +3.62%
on 01/17/18
14.45 -20.76%
on 01/03/18
-0.33 (-2.80%)
since 12/19/17
3-Month
9.40 +21.81%
on 10/27/17
15.14 -24.35%
on 12/04/17
+1.79 (+18.53%)
since 10/19/17
52-Week
5.42 +111.25%
on 08/14/17
25.95 -55.88%
on 04/13/17
-6.66 (-36.78%)
since 01/19/17

Most Recent Stories

More News
Technical Perspectives on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Agile Therapeutics, and Zynerba Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on FCSC, GALT, AGRX, and ZYNE which can be accessed for free by signing up to http://www.wallstequities.com/registration....

AGRX : 3.54 (+2.02%)
GALT : 5.64 (-2.93%)
ZYNE : 11.45 (+0.17%)
FCSC : 0.72 (-3.36%)
Legalization Boost Sales in Cannabis Products

A report published by Ameri Research Inc. indicates that the global legal cannabis market was valued at $14.3 billion in 2016 and is forecast to grow at a CAGR of 21.1% between 2017 and 2024, culminating...

CARA : 13.00 (+4.50%)
PRMCF : 7.9600 (-1.73%)
PVOTF : 2.0000 (+12.36%)
GWPH : 132.42 (+0.33%)
ZYNE : 11.45 (+0.17%)
4 Best Marijuana Stocks to Play the Green Rush

Given the increasing bullish environment, the movement to legalize marijuana has definitely picked up steam. Below are four cannabis-linked stocks that are poised to benefit from legalization.

CRBP : 8.25 (+3.77%)
BAC : 31.72 (+0.76%)
INSY : 8.69 (+1.88%)
ABBV : 104.64 (+0.80%)
ZYNE : 11.45 (+0.17%)
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

- Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders -

ZYNE : 11.45 (+0.17%)
The Value of Medical Cannabis Products Are Expected to Rise

According to Hexa Research, the U.S. medical cannabis market was valued at USD 5.44 billion in 2016 and is expected to be valued at USD 19.48 billion by 2024. Numerous medical benefits of cannabis deal...

CBDS : 6.0800 (-1.94%)
CRBP : 8.25 (+3.77%)
PVOTF : 2.0000 (+12.36%)
GWPH : 132.42 (+0.33%)
ZYNE : 11.45 (+0.17%)
Biotech Market Banking on Big Cannabis Returns

Relatively insulated from economic cycles, the innovation of today's biotech companies puts them in a position to potentially deliver outsized returns regardless of overall conditions. Medicinal cannabis,...

IMLFF : 1.2100 (-0.82%)
CARA : 13.00 (+4.50%)
ISOLF : 0.9750 (-3.26%)
ISOL.CN : 1.220 (-1.61%)
GWPH : 132.42 (+0.33%)
ZYNE : 11.45 (+0.17%)
IN.CN : 1.540 (+1.99%)
Research Predicts Further Growth for the Medical Cannabis Market

According to a report by Forbes, Brightfield Group, a cannabis market research firm, the international market for cannabis is expected to be valued $31.4 billion by 2021. Bethany Gomez, Director of Research...

ACAN : 3.7500 (+3.31%)
CRBP : 8.25 (+3.77%)
CARA : 13.00 (+4.50%)
GWPH : 132.42 (+0.33%)
ZYNE : 11.45 (+0.17%)
Canada Could be on the Cusp of a Cannabis Revolution

The world has a pot problem. Quite simply: there isn't enough of it, legal and accessible, to meet the tidal wave of demand that is about to sweep across North America. After the campaign promises of Prime...

IIPR : 28.17 (-0.70%)
INSY : 8.69 (+1.88%)
TEVA : 20.70 (-0.05%)
SMG : 106.28 (-0.75%)
ZYNE : 11.45 (+0.17%)
Technical Perspectives on Horizon Pharma, Akari Therapeutics, MYOS RENS Technology, and Zynerba Pharma

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on HZNP, AKTX, MYOS, and ZYNE which is a click away at www.wallstequities.com/registration....

AKTX : 3.59 (-0.28%)
MYOS : 1.60 (+6.67%)
HZNP : 15.04 (-1.12%)
ZYNE : 11.45 (+0.17%)
Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain

The $58.6 billion global market for pain management drugs is on track to hit upward of $77.1 billion by 2023 on a 4 percent CAGR. North America was the largest segment of this massive market last year,...

IMLFF : 1.2100 (-0.82%)
CARA : 13.00 (+4.50%)
AXIM : 8.1300 (-0.85%)
GWPH : 132.42 (+0.33%)
ZYNE : 11.45 (+0.17%)
IN.CN : 1.540 (+1.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 11.72
1st Resistance Point 11.58
Last Price 11.45
1st Support Level 11.23
2nd Support Level 11.02

See More

52-Week High 25.95
Fibonacci 61.8% 18.11
Fibonacci 50% 15.69
Fibonacci 38.2% 13.26
Last Price 11.45
52-Week Low 5.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.